Partial Oral Antibiotic Therapy for Infective Endocarditis: A Practical Review of Current Evidence and Guidelines
Abstract
Infective endocarditis (IE) is associated with an in-hospital mortality rate of 15-30%. Standard treatment requires 2 to 6 weeks of intravenous (IV) antibiotic therapy, resulting in prolonged hospitalization with its attendant risks, including catheter-related complications, increased length of stay, and cost. This review summarizes the current evidence, eligibility criteria, antibiotic regimen selection, and practical aspects of partial oral antibiotic therapy (POAT) for IE. Oral treatment is already recommended for right-sided Staphylococcus aureus IE and IE caused by selected atypical pathogens (e.g., Brucella spp., Coxiella burnetii, Bartonella spp., and Tropheryma whipplei). The landmark Partial Oral Treatment of Endocarditis trial (2019) demonstrated the non-inferiority of POAT-initiated after at least 10 days of IV therapy-versus continued IV treatment for left-sided IE caused by streptococci, Enterococcus faecalis, S. aureus, or coagulase-negative staphylococci. Long-term follow-up at 5.4 years demonstrated lower all-cause mortality in the POAT group. The 2023 European Society of Cardiology Guidelines now formally endorse POAT for selected patients fulfilling strict criteria. Despite robust evidence, POAT is currently implemented in fewer than half of eligible patients. These findings have since been corroborated by the WikiGuidelines Group consensus statement and the French Société de Pathologie Infectieuse de Langue Française-Association pour l'Étude et la…
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.